论文部分内容阅读
很多回顾性随机研究已经显示:与常规化疗相比,α干扰素(IFN-α)治疗慢性粒细胞白血病(CML)可延长生存期。然而,IFN-α虽然能引起细胞遗传学反应,但很少能达到真正的完全缓解。有关IFN-α治疗长期效果的文献很少。因此,我们总结分析1986年开始的IFN-α与常规化疗的回顾对比性试验。试验的第1次分析结果已经发表,显示IFN-α治疗生存期延长。(N Engl J Med,1994;12:820)。 病例和方法;这个研究持续2年,322例病人随机接受治疗,其中IFN-α治疗218例,常规化疗104例。IFN-α组使用人重组IFN-α2a900万u/天,至少使用14个月,有细胞遗传学反应
Many retrospective randomized studies have shown that interferon alpha (IFN-alpha) treatment of chronic myelogenous leukemia (CML) prolongs survival compared to conventional chemotherapy. However, although IFN-α can cause cytogenetic reactions, it rarely achieves true complete remission. There are few literatures on the long-term effects of IFN-α treatment. Therefore, we reviewed the retrospective comparative trials of IFN-α and conventional chemotherapy that began in 1986. The results of the first analysis of the trial have been published, showing that the survival of IFN-α treatment is prolonged. (N Engl J Med, 1994; 12:820). Cases and Methods; This study lasted for 2 years and 322 patients were randomized to treatment, of which 218 were treated with IFN-α and 104 were treated with conventional chemotherapy. Human recombinant IFN-α2a 9 million u/day in the IFN-α group for at least 14 months with cytogenetic response